Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, explains how the Biologics Price Competition and Innovation Act (BPCIA) has impacted the industry.
Transcript:
I think it's certainly the changes and the new regulatory pathway has certainly helped us as an industry continue to refine and move forward. I think there's some definite advantages for biosimilars in terms of what those hurdles actually are from a safety and efficacy perspective without at all compromising patient safety or what the true requirements are. I mean, the fact that we have to do comparative trials to demonstrate that there's no difference between the efficacy and safety that we have versus an originator across multiple batches, right, is pretty significant, and I think should lend a lot of credibility and confidence to the marketplace.
At the same time, I think we're still learning, right? So, from a drug development perspective, when you're looking at these kinds of investments, which are significant, I mean, we're running clinical trials like an originator would, I think that we're looking at things like how do we use extrapolation or do we have to do these trials around interchangeability that I think the FDA's still working on. How are we going to overcome some of those kinds of challenges?
And especially for the United States to be able to benefit from the simplicity of the European system, I think those are some of the things that we think could certainly add a great deal of policy information to speed along some of those changes. But for sure the openness in Washington right now to working with our industry to making sure that it's not a standard generic. It's not pill pressing. It is a biologic that requires the right kind of hurdles in order to make sure. And manufacturing these things, not easy, right? It's a very difficult process, and we take it very seriously. I think for Sandoz we're really lucky, because we have the benefit of our parent company as well as our own 35 years' worth of experience in this area. So we're certainly leveraging all of that, and then the openness to work with government in order to make it as smooth and as robust as we possibly can. So we're excited about the changes that have happened in the United States.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient With MS Sues J&J Over ERISA Violation
February 14th 2024After a patient with multiple sclerosis (MS) was forced to pay exorbitant out-of-pocket costs for a brand name medication when she could’ve gotten a generic for way less, the patient filed a class action complaint against her employer, Johnson & Johnson (J&J), for violating the Employee Retirement Income Security Act of 1974 (ERISA).
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Eye on Pharma: Fresh Biosimilar Lawsuits; FDA to Review Ustekinumab, Denosumab Biosimilars
January 11th 2024As Regeneron gears up for a legal battle with biosimilar competitors for its reference aflibercept, CareFirst files a lawsuit against Johnson & Johnson for restricting biosimilar ustekinumab competition; Celltrion and Accord BioPharma file with the FDA to approve their respective biosimilar candidates.